8-K/A

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2013

ONCOLOGIX TECH, INC.

(Name of Small Business Issuer as Specified in Its Charter)

Nevada 0-15482 86-1006416

(State or other jurisdiction of (Commission File Number) (I.R.S. Employer

Organization or Incorporation) Identification Number)

1604 West Pinhook Drive

Suite # 200

Lafayette, Louisiana 70508

(Address of principal executive offices)

(616) 977-9933

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note – This current report on Form 8-K is being amended to include the financial statements and Pro Forma financial information required by Regulation S-K.

ITEM 9.01 – Financial Statements and Exhibits

(a) Financial Statements of Business Acquired

Angels of Mercy, Inc.

Financial Statements

Year Ended December 31, 2012

Contents

Report of Seale & Beers, CPAs, Independent Registered Public Accounting Firm	F-1
Audited Financial Statements
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Changes in Stockholders' Deficit	F-5
Statements of Cash Flows	F-6
Notes to Financial Statements	F-7

PCAOB Registered Auditors – www.sealebeers.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Angels of Mercy, Inc.

We have audited the accompanying balance sheets of Angels of Mercy, Inc. as of December 31, 2012, and the related statements of income, stockholders’ equity (deficit), and cash flows for the period ended December 31, 2012. Angels of Mercy, Inc.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Angels of Mercy, Inc. as of December 31, 2012, and the related statements of income, stockholders’ equity (deficit), and cash flows for the year ended December 31, 2012, in conformity with accounting principles generally accepted in the United States of America.

/s/ Seale and Beers, CPAs

Seale and Beers, CPAs

Las Vegas, Nevada

December 18, 2014

ANGELS OF MERCY, INC.

BALANCE SHEET

AS OF DECEMBER 31, 2012

	December 31,
	2012
ASSETS
Current Assets:
Cash and cash equivalents	$	18,420
Accounts receivable (net of allowance of $3,000)		225,593
Inventory		—
Prepaid expenses and other current assets		(75	)
Total current assets		243,938
Property and equipment (net of accumulated depreciation
of $67,508)		30,079
Total assets	$	274,017
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit payable	$	22,100
Accounts payable and accrued expenses		86,510
Total current liabilities		108,610
Total liabilities		108,610
Stockholders' equity:
Common stock, par value $1.00 per share; 1,000 shares authorized;
1,000 and 1,000 shares issued and outstanding at
December 31, 2012		1,000
Additional paid-in capital		14,368
Accumulated earnings		150,039
Total stockholders' equity		165,407
Total liabilities and stockholders' equity		274,017

See accompanying notes to financial statements.

ANGELS OF MERCY, INC.

STATEMENTS OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2012

	For the Year Ended
	December 31,
	2012
Revenues	$	2,948,677
Cost of revenues		2,501,430
Gross profit		447,247
Operating expenses:
General and administrative		484,779
Depreciation and amortization		1,868
Total operating expenses		486,647
Loss from operations		(39,400	)
Other income (expense):
Interest income		114
Interest and finance charges		(1,437	)
Total other income (expense)		(1,323	)
Net loss before income taxes		(40,723	)
Income taxes		—
Net loss attributable to common shareholders	$	(40,723	)
Loss per common share, basic and diluted:	$	(40.72	)
Weighted average number of shares
outstanding - basic and diluted		1,000

See accompanying notes to financial statements.

ANGELS OF MERCY, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE PERIOD JANUARY 1, 2012 THROUGH DECEMBER 31, 2012

	Common Stock				Additional Paid-in		Accumulated Earnings
	Shares		Amount		Capital		(Deficit)			Total
Balance, December 31, 2011	1,000	$	1,000	$	14,368	$	190,762		$	206,130
Net loss	—		—		—		(40,723	)		(40,723	)
Balance, December 31, 2012	1,000	$	1,000	$	14,368	$	150,039		$	165,407

See accompanying notes to financial statements

ANGELS OF MERCY, INC.

STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2012

	For the Year Ended
	December 31,
	2012
Operating activities:
Net income	$	(40,723	)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization		1,868
Changes in operating assets and liabilities:
Accounts receivable		(118,765	)
Prepaid expenses and other current assets		15,986
Accounts payable		86,510
Net cash used in operating activities		(55,124	)
Investing activities:
Purchase of property and equipment		—
Net cash used in investing activities		—
Financing activities:
Repayment of notes payable		(24,412	)
Net cash provided by financing activities		(24,412	)
Net increase (decrease) in cash and cash equivalents		(79,536	)
Cash and cash equivalents, beginning of period		97,956
Cash and cash equivalents, end of period	$	18,420

See accompanying notes to financial statements.

ANGELS OF MERCY, INC.

NOTES TO FINANCIAL STATEMENTS

NOTE 1 — DESCRIPTION OF THE COMPANY

General

Angels of Mercy provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).

PCA services that are reimbursed to AOM under the waiver:

· Assisting with personal hygiene, dressing, bathing, and grooming

· Performing or assisting in the performance of tasks related to maintaining a safe, healthy and stable living environment such as:

· Light cleaning tasks in areas of the home used by the recipient,

· Shopping for such items as health and hygiene products, clothing and groceries,

· Performing activities of daily living inside and outside of the home which require attendant care,

· Assisting with or performing beneficiary laundry care chores

· Assisting with bladder and/or bowel requirements, including bed pan routines

· If indicated on the Plan of Care, assisting beneficiary to clinics, physician’s offices, and other appointments,

· Assisting the beneficiary to receive any service specified in the written Plan of Care, including leisure skills development,

· Assisting in activities which would enhance the individual employability and improve and enhance the beneficiary’s quality of life.

Supervised Independent Living (SIL) is an alternative program for mentally challenged, developmentally disabled or physically disabled individuals. AOM provides the following personal health services:

· Assistance with safety procedures and emergency contacts within the home environment

· Counseling during the transition period

· Assistance in meeting needs with medical management, employment, financial, budgeting, household management, personal care, recreation and transportation

· Accessibility to community resources

· Independence and personal growth

· Freedom from abuse, neglect and exploitation

Services and Fee Structure

AOM is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for AOM to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program.

Long Term Care (LTC) - Older population or anyone whose disability occurred after their 21st birthday. Reimbursement rate: $2.89/quarter hour

Early Periodic Screening Diagnostic Treatment (EPSDT) – This service is provided from 3 years of age or older until 21 years of age. Reimbursement rate: $2.53/quarter hour

Elderly and Young Adult Waiver (EDA) – This service is provided by age 22 and normally up through death of the client. Reimbursement rate: $2.83/quarter hour

New Opportunity Waiver (NOW) The longest running Medicaid Waiver program and has the most resources available for the clients.

Several programs within the NOW- Title 19.

Reimbursement rates:

IFS day program: $3.61/quarter hour

IFS night: $2.17quarter hour

IFS day x2: $2.72/quarter hour

IFS day x3: 2.36/quarter hour

IFS night x2: $1.52/quarter hour

Supervised Independent Living (SIL) - Clients live independently but with supervision and assistance from AOM trained staff. Activities of Daily Living skills are taught by staff to clients. Some clients go to day programs, some are employed, and some clients receive 24 hours/day personal care services. Reimbursement rate: 16.93/hour/daily care 24/7.

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.

USE OF ESTIMATES

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

REVENUE RECOGNITION

Revenue is recognized by the Company when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently the company does not have products to sell.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.

ACCOUNTS RECEIVABLE

Receivables are generally collected within 14 days of billing to the State of Louisiana. Rejected claims are and maybe resubmitted up to a year following the initial billing claim. The Company reviews its outstanding claims

on an annual basis and adjusts them appropriately. Currently the company maintains a reserve of $3,000 for rejected claims.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

Furniture and fixtures	5 to 10 years
Computer equipment	5 years
Equipment	5 to 10 years
Software	3 to 5 years

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.

ADVERTISING COSTS

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were $1,189 for the year ended December 31, 2012. Such costs are expensed when incurred.

INCOME TAXES

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current year presentation.

RECENT ACCOUNTING PRONOUNCEMENTS

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

NEW ACCOUNTING STANDARD

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.

ANGELS OF MERCY, INC.

NOTES TO FINANCIAL STATEMENTS

NOTE 3 — STOCKHOLDERS EQUITY

COMMON STOCK:

The Company has authorized 1,000 shares of $1.00 par value common stock. As of December 31, 2012, there are 1,000 shares issued and outstanding.

NOTE 4 – STATEMENT OF CASH FLOWS

For the year ended December 31, 2012, there are no supplemental non-cash investing and financing activities disclosures.

NOTE 5 — SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and there are no other material subsequent events to report except the following:

On August 1, 2013, the Oncologix Tech, Inc., a publicly traded company, acquired all of the outstanding shares of common stock of ANGELS OF MERCY, INC. (“Dotolo”), a personal care company. The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include goodwill. The purchase price consisted of the following: a) payment of $100,000 cash at closing; b) issuance of a promissory note in the amount of $550,000; c) issuance of one million warrants to purchase the common stock of Oncologix Tech, Inc. with an exercise price of $0.015; d) payment of $65,000 in broker fees.

The purchase price was allocated to assets acquired and liabilities assumed as follows:

Cash and cash equivalents	$	27,121
Accounts receivable (net)		111,581
Prepaid expenses and other current assets		7,851
Property and equipment		57,000
Purchased goodwill		478,721
Total assets acquired	$	682,274
Accounts payable and other accrued expenses	$	9,688
Total liabilities assumed	$	9,688

NOTE 6 - INCOME TAXES

As of December 31, 2012, the Company has federal general business credit carryforwards totaling approximately $145,000. The general business credit carry-forwards expire in various amounts beginning in 2027 and ending in 2030. The Company does not have any current state net operating loss carry-forwards.

ASC 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. As a result of the implementation of ASC 740 – Income Taxes, the Company performed a review of its material tax positions. At the adoption date of ASC 740, the Company had no unrecognized tax benefit which would affect the effective tax rate.  December 31, 2012, the Company had no accrued interest and penalties related to uncertain tax positions. The Company is primarily subject to U.S. and Louisiana income taxes. The tax years 2011 to current remain open to examination by U.S. federal and state tax authorities.

(b) Pro Forma Financial Information

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF AUGUST 31, 2012

		For the year ended August 31, 2012
			Pro Forma
		Historical	Adjustments		Pro Forma
Revenues		$                         -	$          2,860,429	(A)	$             195,067
Cost of revenues		-	2,362,245	(A)	-
	Gross profit	-	498,184		195,067
	General and administrative	130,769	517,813	(A)	195,067
	Depreciation and amortization	450	1,245	(A)	1,471
	Total operating expenses	131,219	519,058		196,538
	Loss from operations	(131,219)	(20,874)		(1,471)
Other income (expense):
	Interest and finance charges	(10,768)	(1,437)	(A)	(14,707)
	Interest and finance charges - related parties	(25,312)	-		(18,241)
	Loss on conversion of notes payable - related parties	(92,758)	-		-
	Induced conversion expense	(25,402)	-		(6,076)
	Loss on disposal of assets	(110)	-		-
	Other expenses	-	10,146	(A)	(47)
	Total other income (expense)	(154,350)	8,709		(39,071)
Loss from operations		(285,569)	(12,165)		(40,542)
	Less loss attributable to noncontrolling interest	(14)	-		(13)
Net loss before income taxes		(285,555)	(12,165)		(40,529)
Income taxes		-	-		-
Net loss attributable to common shareholders		$           (285,555)	$             (12,165)		$             (40,529)
Loss per common share, basic and diluted:		$                 (0.01)			$                 (0.00)
Weighted average number of shares
	outstanding - basic and diluted	54,443,649			47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	27,484	(B)	$	29,415
Accounts receivable (net of $3,000 allowance)		—			423,915	(B)		423,915
Prepaid expenses and other current assets		2,993			4,090	(B)		7,083
Total current assets		4,924			455,489			460,413
Property and equipment (net of accumulated depreciation)		1,481			46,845	(B)		48,326
Total assets	$	6,405		$	502,334		$	508,739
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	—		$	—
Accounts payable and other accrued expenses		142,990			18,542	(B)		161,532
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			18,542			252,323
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			18,542			612,348
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized
129,062 and 129,062 shares issued and outstanding at
August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(B)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		468,424	(B)		134,442
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		483,792			(103,609	)
Total liabilities and stockholders' deficit	$	6,405		$	502,334		$	508,739

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2012

	For the year ended August 31, 2012
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	53,805	(A)	$	55,736
Accounts receivable (net of allowance)		—			222,664	(A)		222,664
Prepaid expenses and other current assets		2,993			—			2,993
Total current assets		4,924			276,469			281,393
Property and equipment (net of accumulated depreciation)		1,481			30,701	(A)		32,182
Total assets	$	6,405		$	307,170		$	313,575
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	41,612	(A)	$	41,612
Accounts payable and other accrued expenses		142,990			11,163	(A)		154,153
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			52,775			286,556
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			52,775			646,581
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(A)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		239,027	(A)		(94,955	)
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		254,395			(333,006	)
Total liabilities and stockholders' deficit	$	6,405		$	307,170		$	313,575

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
Revenues	$	—		$	2,875,579	(B)	$	195,067
Cost of revenues		—			2,339,789	(B)		—
Gross profit		—			535,790			195,067
General and administrative		130,769			548,380	(B)		195,067
Depreciation and amortization		450			—			1,471
Total operating expenses		131,219			548,380			196,538
Loss from operations		(131,219	)		(12,590	)		(1,471	)
Other income (expense):
Interest and finance charges		(10,768	)		(124	)(B)		(14,707	)
Interest and finance charges - related parties		(25,312	)		—			(18,241	)
Loss on conversion of notes payable - related parties		(92,758	)		—			—
Induced conversion expense		(25,402	)		—			(6,076	)
Loss on disposal of assets		(110	)		—			—
Other expenses		—			1,945	(B)		(47	)
Total other income (expense)		(154,350	)		1,821			(39,071	)
Loss from operations		(285,569	)		(10,769	)		(40,542	)
Less loss attributable to noncontrolling interest		(14	)		—			(13	)
Net loss before income taxes		(285,555	)		(10,769	)		(40,529	)
Income taxes		—			—			—
Net loss attributable to common shareholders	$	(285,555	)	$	(10,769	)	$	(40,529	)
Loss per common share, basic and diluted:	$	(0.01	)				$	(0.00	)
Weighted average number of shares
outstanding - basic and diluted		54,443,649						47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following is a description of the pro forma adjustments to the historical condensed consolidated financial statements.

A. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

B. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: January 14, 2015
	ONCOLOGIX TECH, INC.
	By: /s/ Roy Wayne Erwin
	Roy Wayne Erwin, Chief Executive Officer
	By:      /s/ Michael A. Kramarz
	Michael A. Kramarz, Chief Financial Officer

XML

Pro Forma Financial Information (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Historical
Revenues
Cost of revenues
Gross profit
General and administrative	130,769	130,769
Depreciation and amortization	450	450
Total operating expenses	131,219	131,219
Loss from operations	(131,219)	(131,219)
Other income (expense):
Interest and finance charges	(10,768)	(10,768)
Interest and finance charges - related parties	(25,312)	(25,312)
Loss on conversion of notes payable - related parties	(92,758)	(92,758)
Induced conversion expense	(25,402)	(25,402)
Loss on disposal of assets	(110)	(110)
Other expenses
Total other income (expense)	(154,350)	(154,350)
Loss from operations	(285,569)	(285,569)
Less loss attributable to noncontrolling interest	(14)	(14)
Net loss before income taxes	(285,555)	(285,555)
Income taxes
Net loss attributable to common shareholders	(285,555)	(285,555)
Loss per common share, basic and diluted:	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding - basic and diluted	54,443,649	54,443,649
Pro Forma Adjustment
Revenues	2,860,429	2,875,579
Cost of revenues	2,362,245	2,339,789
Gross profit	498,184	535,790
General and administrative	517,813	548,380
Depreciation and amortization	1,245
Total operating expenses	519,058	548,380
Loss from operations	(20,874)	(12,590)
Other income (expense):
Interest and finance charges	(1,437)	(124)
Interest and finance charges - related parties
Loss on conversion of notes payable - related parties
Induced conversion expense
Loss on disposal of assets
Other expenses	10,146	1,945
Total other income (expense)	8,709	1,821
Loss from operations	(12,165)	(10,769)
Less loss attributable to noncontrolling interest
Net loss before income taxes	(12,165)	(10,769)
Income taxes
Net loss attributable to common shareholders	(12,165)	(10,769)
Pro Forma
Revenues	195,067	195,067
Cost of revenues
Gross profit	195,067	195,067
General and administrative	195,067	195,067
Depreciation and amortization	1,471	1,471
Total operating expenses	196,538	196,538
Loss from operations	(1,471)	(1,471)
Other income (expense):
Interest and finance charges	(14,707)	(14,707)
Interest and finance charges - related parties	(18,241)	(18,241)
Loss on conversion of notes payable - related parties
Induced conversion expense	(6,076)	(6,076)
Loss on disposal of assets
Other expenses	(47)	(47)
Total other income (expense)	(39,071)	(39,071)
Loss from operations	(40,542)	(40,542)
Less loss attributable to noncontrolling interest	(13)	(13)
Net loss before income taxes	(40,529)	(40,529)
Income taxes
Net loss attributable to common shareholders	$ (40,529)	$ (40,529)
Loss per common share, basic and diluted:	$ 0.00	$ 0.00
Weighted average number of shares outstanding - basic and diluted	47,915,734	47,915,734

XML

STOCKHOLDERS EQUITY

12 Months Ended

Dec. 31, 2012

Equity [Abstract]

STOCKHOLDERS EQUITY

NOTE 3 — STOCKHOLDERS EQUITY

COMMON STOCK:

The Company has authorized 1,000 shares of $1.00 par value common stock. As of December 31, 2012, there are 1,000 shares issued and outstanding.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.

USE OF ESTIMATES

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

REVENUE RECOGNITION

Revenue is recognized by the Company when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently the company does not have products to sell.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.

ACCOUNTS RECEIVABLE

Receivables are generally collected within 14 days of billing to the State of Louisiana. Rejected claims are and maybe resubmitted up to a year following the initial billing claim. The Company reviews its outstanding claims

on an annual basis and adjusts them appropriately. Currently the company maintains a reserve of $3,000 for rejected claims.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

Furniture and fixtures	5 to 10 years
Computer equipment	5 years
Equipment	5 to 10 years
Software	3 to 5 years

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.

ADVERTISING COSTS

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were $1,189 for the year ended December 31, 2012. Such costs are expensed when incurred.

INCOME TAXES

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current year presentation.

RECENT ACCOUNTING PRONOUNCEMENTS

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

NEW ACCOUNTING STANDARD

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.

XML

Balance Sheets (Angels of Mercy, Inc., USD $)	Dec. 31, 2012
Angels of Mercy, Inc.
Current Assets:
Cash and cash equivalents	$ 18,420
Accounts receivable (net of allowance of $3,000)	225,593
Inventory
Prepaid expenses and other current assets	(75)
Total current assets	243,938
Property and equipment (net of accumulated depreciation of $67,508)	30,079
Total assets	274,017
Current liabilities:
Line of credit payable	22,100
Accounts payable and accrued expenses	86,510
Total current liabilities	108,610
Total liabilities	108,610
Stockholders' equity:
Common stock, par value $1.00 per share; 1,000 shares authorized;1,000 and 1,000 shares issued and outstanding at December 31, 2012	1,000
Additional paid-in capital	14,368
Accumulated earnings	150,039
Total stockholders' equity	165,407
Total liabilities and stockholders' equity	$ 274,017

XML

Statements of Cash Flows (Angels of Mercy, Inc., USD $)	12 Months Ended
	Dec. 31, 2012
Angels of Mercy, Inc.
Operating activities:
Net income	$ (40,723)
Depreciation and amortization	1,868
Changes in operating assets and liabilities:
Accounts receivable	(118,765)
Prepaid expenses and other current assets	15,986
Accounts payable	86,510
Net cash used in operating activities	(55,124)
Purchase of property and equipment
Net cash used in investing activities
Financing activities:
Repayment of notes payable	(24,412)
Net cash provided by financing activities	(24,412)
Net increase (decrease) in cash and cash equivalents	(79,536)
Cash and cash equivalents, beginning of period	97,956
Cash and cash equivalents, end of period	$ 18,420

XML

INCOME TAXES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal net operating loss carryforward	$ 145,000
Carryforward Expriation	Dec. 31, 2030

XML

Pro Forma Financial Information (Details 1) (Parenthetical) (Pro Forma, USD $)	Aug. 31, 2012	Aug. 31, 2011
Pro Forma
Allowance for doubtful accounts receivable	$ 3,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	57,563,258	50,998,814
Common stock, shares outstanding	57,563,258	50,998,814

XML

DESCRIPTION OF THE COMPANY

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

DESCRIPTION OF THE COMPANY

NOTE 1 — DESCRIPTION OF THE COMPANY

General

Angels of Mercy provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).

PCA services that are reimbursed to AOM under the waiver:

· Assisting with personal hygiene, dressing, bathing, and grooming

· Performing or assisting in the performance of tasks related to maintaining a safe, healthy and stable living environment such as:

· Light cleaning tasks in areas of the home used by the recipient,

· Shopping for such items as health and hygiene products, clothing and groceries,

· Performing activities of daily living inside and outside of the home which require attendant care,

· Assisting with or performing beneficiary laundry care chores

· Assisting with bladder and/or bowel requirements, including bed pan routines

· If indicated on the Plan of Care, assisting beneficiary to clinics, physician’s offices, and other appointments,

· Assisting the beneficiary to receive any service specified in the written Plan of Care, including leisure skills development,

· Assisting in activities which would enhance the individual employability and improve and enhance the beneficiary’s quality of life.

Supervised Independent Living (SIL) is an alternative program for mentally challenged, developmentally disabled or physically disabled individuals. AOM provides the following personal health services:

· Assistance with safety procedures and emergency contacts within the home environment

· Counseling during the transition period

· Assistance in meeting needs with medical management, employment, financial, budgeting, household management, personal care, recreation and transportation

· Accessibility to community resources

· Independence and personal growth

· Freedom from abuse, neglect and exploitation

Services and Fee Structure

AOM is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for AOM to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program.

Long Term Care (LTC) - Older population or anyone whose disability occurred after their 21st birthday. Reimbursement rate: $2.89/quarter hour

Early Periodic Screening Diagnostic Treatment (EPSDT) – This service is provided from 3 years of age or older until 21 years of age. Reimbursement rate: $2.53/quarter hour

Elderly and Young Adult Waiver (EDA) – This service is provided by age 22 and normally up through death of the client. Reimbursement rate: $2.83/quarter hour

New Opportunity Waiver (NOW) The longest running Medicaid Waiver program and has the most resources available for the clients.

Several programs within the NOW- Title 19.

Reimbursement rates:

IFS day program: $3.61/quarter hour

IFS night: $2.17quarter hour

IFS day x2: $2.72/quarter hour

IFS day x3: 2.36/quarter hour

IFS night x2: $1.52/quarter hour

Supervised Independent Living (SIL) - Clients live independently but with supervision and assistance from AOM trained staff. Activities of Daily Living skills are taught by staff to clients. Some clients go to day programs, some are employed, and some clients receive 24 hours/day personal care services. Reimbursement rate: 16.93/hour/daily care 24/7.

XML

Balance Sheets (Parenthetical) (Angels of Mercy, Inc., USD $)	Dec. 31, 2012
Angels of Mercy, Inc.
Allowance for doubtful accounts receivable	$ 3,000
Property and equipment, accumulated depreciation	$ 67,508
Common stock, par value	$ 1.00
Common stock, shares authorized	1,000
Common stock, shares issued	1,000
Common stock, shares outstanding	1,000

XML

DESCRIPTION OF THE COMPANY (Details Narrative)

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

Terms of services

AOM is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for AOM to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program.

Long Term Care (LTC) - Older population or anyone whose disability occurred after their 21st birthday. Reimbursement rate: $2.89/quarter hour

Early Periodic Screening Diagnostic Treatment (EPSDT) – This service is provided from 3 years of age or older until 21 years of age. Reimbursement rate: $2.53/quarter hour

Elderly and Young Adult Waiver (EDA) – This service is provided by age 22 and normally up through death of the client. Reimbursement rate: $2.83/quarter hour

New Opportunity Waiver (NOW) The longest running Medicaid Waiver program and has the most resources available for the clients.

Several programs within the NOW- Title 19.

Reimbursement rates:

IFS day program: $3.61/quarter hour

IFS night: $2.17quarter hour

IFS day x2: $2.72/quarter hour

IFS day x3: 2.36/quarter hour

IFS night x2: $1.52/quarter hour

Supervised Independent Living (SIL) - Clients live independently but with supervision and assistance from AOM trained staff. Activities of Daily Living skills are taught by staff to clients. Some clients go to day programs, some are employed, and some clients receive 24 hours/day personal care services. Reimbursement rate: 16.93/hour/daily care 24/7.

XML

Document and Entity Information

12 Months Ended

Dec. 31, 2012

Document And Entity Information

Entity Registrant Name

Oncologix Tech Inc.

Entity Central Index Key

0000799694

Document Type

8-K

Document Period End Date

Dec. 31, 2012

Amendment Flag

true

Current Fiscal Year End Date

--12-31

Is Entity a Well-known Seasoned Issuer?

No

Is Entity a Voluntary Filer?

No

Is Entity's Reporting Status Current?

Yes

Entity Filer Category

Smaller Reporting Company

Document Fiscal Period Focus

FY

Document Fiscal Year Focus

2012

Amendment Description

This current report on Form 8-K is being amended to include the financial statements and Pro Forma financial information required by Regulation S-K.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (Angels of Mercy, Inc., USD $)	12 Months Ended
	Dec. 31, 2012
Angels of Mercy, Inc.
Days to collect receivables	14 days
Allowance for doubtful accounts receivable	$ 3,000
Advertising costs	$ 1,189

XML

Statements of Operations (Angels of Mercy, Inc., USD $)	12 Months Ended
	Dec. 31, 2012
Angels of Mercy, Inc.
Revenues	$ 2,948,677
Cost of revenues	2,501,430
Gross profit	447,247
Operating expenses:
General and administrative	484,779
Depreciation and amortization	1,868
Total operating expenses	486,647
Loss from operations	(39,400)
Other income (expense):
Interest income	114
Interest and finance charges	(1,437)
Total other income (expense)	(1,323)
Net loss before income taxes	(40,723)
Income taxes
Net loss attributable to common shareholders	$ (40,723)
Loss per common share, basic and diluted:	$ (40.72)
Weighted average number of shares outstanding - basic and diluted	1,000

XML

INCOME TAXES

12 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 6 - INCOME TAXES

As of December 31, 2012, the Company has federal general business credit carryforwards totaling approximately $145,000. The general business credit carry-forwards expire in various amounts beginning in 2027 and ending in 2030. The Company does not have any current state net operating loss carry-forwards.

ASC 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. As a result of the implementation of ASC 740 – Income Taxes, the Company performed a review of its material tax positions. At the adoption date of ASC 740, the Company had no unrecognized tax benefit which would affect the effective tax rate.  December 31, 2012, the Company had no accrued interest and penalties related to uncertain tax positions. The Company is primarily subject to U.S. and Louisiana income taxes. The tax years 2011 to current remain open to examination by U.S. federal and state tax authorities.

XML

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2012

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 5 — SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and there are no other material subsequent events to report except the following:

On August 1, 2013, the Oncologix Tech, Inc., a publicly traded company, acquired all of the outstanding shares of common stock of ANGELS OF MERCY, INC. (“Dotolo”), a personal care company. The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include goodwill. The purchase price consisted of the following: a) payment of $100,000 cash at closing; b) issuance of a promissory note in the amount of $550,000; c) issuance of one million warrants to purchase the common stock of Oncologix Tech, Inc. with an exercise price of $0.015; d) payment of $65,000 in broker fees.

The purchase price was allocated to assets acquired and liabilities assumed as follows:

Cash and cash equivalents	$	27,121
Accounts receivable (net)		111,581
Prepaid expenses and other current assets		7,851
Property and equipment		57,000
Purchased goodwill		478,721
Total assets acquired	$	682,274
Accounts payable and other accrued expenses	$	9,688
Total liabilities assumed	$	9,688

XML

Pro Forma Financial Information (Details 1) (USD $)	Aug. 31, 2012	Aug. 31, 2011
Historical
Current Assets:
Cash and cash equivalents	$ 1,931	$ 1,931
Accounts receivable (net of $3,000 allowance)
Prepaid expenses and other current assets	2,993	2,993
Total current assets	4,924	4,924
Property and equipment (net of accumulated depreciation)	1,481	1,481
Total assets	6,405	6,405
Current liabilities:
Line of credit payable
Accounts payable and other accrued expenses	142,990	142,990
Accrued interest payable	42,575	42,575
Accrued interest payable - related parties	48,216	48,216
Total current liabilities	233,781	233,781
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)	125,000	125,000
Convertible notes payable - related parties (net of discount of $0 and $0)	235,025	235,025
Total long-term liabilities	360,025	360,025
Total liabilities	593,806	593,806
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively	129	129
Common stock, par value $.001 per share; 200,000,000 shares authorized; 57,563,258 and 50,998,814 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively	57,563	57,563
Additional paid-in capital	57,697,233	57,697,233
Accumulated deficit prior to reentering development stage	(58,004,869)	(58,004,869)
Deficit accumulated during the development stage	(333,982)	(333,982)
Noncontrolling interest	(3,475)	(3,475)
Total stockholders' deficit	(587,401)	(587,401)
Total liabilities and stockholders' deficit	6,405	6,405
Pro Forma Adjustments
Current Assets:
Cash and cash equivalents	27,484	53,805
Accounts receivable (net of $3,000 allowance)	423,915	222,664
Prepaid expenses and other current assets	4,090
Total current assets	455,489	276,469
Property and equipment (net of accumulated depreciation)	46,845	30,701
Total assets	502,334	307,170
Current liabilities:
Line of credit payable		41,612
Accounts payable and other accrued expenses	18,542	11,163
Accrued interest payable
Accrued interest payable - related parties
Total current liabilities	18,542	52,775
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)
Convertible notes payable - related parties (net of discount of $0 and $0)
Total long-term liabilities
Total liabilities	18,542	52,775
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively
Common stock, par value $.001 per share; 200,000,000 shares authorized; 57,563,258 and 50,998,814 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively
Additional paid-in capital	15,368	15,368
Accumulated deficit prior to reentering development stage
Deficit accumulated during the development stage	468,424	239,027
Noncontrolling interest
Total stockholders' deficit	483,792	254,395
Total liabilities and stockholders' deficit	502,334	307,170
Pro Forma
Current Assets:
Cash and cash equivalents	29,415	55,736
Accounts receivable (net of $3,000 allowance)	423,915	222,664
Prepaid expenses and other current assets	7,083	2,993
Total current assets	460,413	281,393
Property and equipment (net of accumulated depreciation)	48,326	32,182
Total assets	508,739	313,575
Current liabilities:
Line of credit payable		41,612
Accounts payable and other accrued expenses	161,532	154,153
Accrued interest payable	42,575	42,575
Accrued interest payable - related parties	48,216	48,216
Total current liabilities	252,323	286,556
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)	125,000	125,000
Convertible notes payable - related parties (net of discount of $0 and $0)	235,025	235,025
Total long-term liabilities	360,025	360,025
Total liabilities	612,348	646,581
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively	129	129
Common stock, par value $.001 per share; 200,000,000 shares authorized; 57,563,258 and 50,998,814 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively	57,563	57,563
Additional paid-in capital	57,712,601	57,712,601
Accumulated deficit prior to reentering development stage	(58,004,869)	(58,004,869)
Deficit accumulated during the development stage	134,442	(94,955)
Noncontrolling interest	(3,475)	(3,475)
Total stockholders' deficit	(103,609)	(333,006)
Total liabilities and stockholders' deficit	$ 508,739	$ 313,575

XML

STOCKHOLDERS EQUITY (Details Narrative) (Angels of Mercy, Inc., USD $)	Dec. 31, 2012
Angels of Mercy, Inc.
Common stock, par value	$ 1.00
Common stock, shares authorized	1,000
Common stock, shares issued	1,000
Common stock, shares outstanding	1,000

XML

SUBSEQUENT EVENTS (Tables)

12 Months Ended

Dec. 31, 2012

Subsequent Events [Abstract]

Purchase Price

Cash and cash equivalents	$	27,121
Accounts receivable (net)		111,581
Prepaid expenses and other current assets		7,851
Property and equipment		57,000
Purchased goodwill		478,721
Total assets acquired	$	682,274
Accounts payable and other accrued expenses	$	9,688
Total liabilities assumed	$	9,688

XML

Pro Forma

12 Months Ended

Dec. 31, 2012

Notes to Financial Statements

Pro Forma

(b) Pro Forma Financial Information

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF AUGUST 31, 2012

		For the year ended August 31, 2012
			Pro Forma
		Historical	Adjustments		Pro Forma
Revenues		$                         -	$          2,860,429	(A)	$             195,067
Cost of revenues		-	2,362,245	(A)	-
	Gross profit	-	498,184		195,067
	General and administrative	130,769	517,813	(A)	195,067
	Depreciation and amortization	450	1,245	(A)	1,471
	Total operating expenses	131,219	519,058		196,538
	Loss from operations	(131,219)	(20,874)		(1,471)
Other income (expense):
	Interest and finance charges	(10,768)	(1,437)	(A)	(14,707)
	Interest and finance charges - related parties	(25,312)	-		(18,241)
	Loss on conversion of notes payable - related parties	(92,758)	-		-
	Induced conversion expense	(25,402)	-		(6,076)
	Loss on disposal of assets	(110)	-		-
	Other expenses	-	10,146	(A)	(47)
	Total other income (expense)	(154,350)	8,709		(39,071)
Loss from operations		(285,569)	(12,165)		(40,542)
	Less loss attributable to noncontrolling interest	(14)	-		(13)
Net loss before income taxes		(285,555)	(12,165)		(40,529)
Income taxes		-	-		-
Net loss attributable to common shareholders		$           (285,555)	$             (12,165)		$             (40,529)
Loss per common share, basic and diluted:		$                 (0.01)			$                 (0.00)
Weighted average number of shares
	outstanding - basic and diluted	54,443,649			47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	27,484	(B)	$	29,415
Accounts receivable (net of $3,000 allowance)		—			423,915	(B)		423,915
Prepaid expenses and other current assets		2,993			4,090	(B)		7,083
Total current assets		4,924			455,489			460,413
Property and equipment (net of accumulated depreciation)		1,481			46,845	(B)		48,326
Total assets	$	6,405		$	502,334		$	508,739
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	—		$	—
Accounts payable and other accrued expenses		142,990			18,542	(B)		161,532
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			18,542			252,323
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			18,542			612,348
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized
129,062 and 129,062 shares issued and outstanding at
August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(B)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		468,424	(B)		134,442
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		483,792			(103,609	)
Total liabilities and stockholders' deficit	$	6,405		$	502,334		$	508,739

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2012

	For the year ended August 31, 2012
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	53,805	(A)	$	55,736
Accounts receivable (net of allowance)		—			222,664	(A)		222,664
Prepaid expenses and other current assets		2,993			—			2,993
Total current assets		4,924			276,469			281,393
Property and equipment (net of accumulated depreciation)		1,481			30,701	(A)		32,182
Total assets	$	6,405		$	307,170		$	313,575
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	41,612	(A)	$	41,612
Accounts payable and other accrued expenses		142,990			11,163	(A)		154,153
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			52,775			286,556
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			52,775			646,581
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(A)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		239,027	(A)		(94,955	)
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		254,395			(333,006	)
Total liabilities and stockholders' deficit	$	6,405		$	307,170		$	313,575

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
Revenues	$	—		$	2,875,579	(B)	$	195,067
Cost of revenues		—			2,339,789	(B)		—
Gross profit		—			535,790			195,067
General and administrative		130,769			548,380	(B)		195,067
Depreciation and amortization		450			—			1,471
Total operating expenses		131,219			548,380			196,538
Loss from operations		(131,219	)		(12,590	)		(1,471	)
Other income (expense):
Interest and finance charges		(10,768	)		(124	)(B)		(14,707	)
Interest and finance charges - related parties		(25,312	)		—			(18,241	)
Loss on conversion of notes payable - related parties		(92,758	)		—			—
Induced conversion expense		(25,402	)		—			(6,076	)
Loss on disposal of assets		(110	)		—			—
Other expenses		—			1,945	(B)		(47	)
Total other income (expense)		(154,350	)		1,821			(39,071	)
Loss from operations		(285,569	)		(10,769	)		(40,542	)
Less loss attributable to noncontrolling interest		(14	)		—			(13	)
Net loss before income taxes		(285,555	)		(10,769	)		(40,529	)
Income taxes		—			—			—
Net loss attributable to common shareholders	$	(285,555	)	$	(10,769	)	$	(40,529	)
Loss per common share, basic and diluted:	$	(0.01	)				$	(0.00	)
Weighted average number of shares
outstanding - basic and diluted		54,443,649						47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

The following is a description of the pro forma adjustments to the historical condensed consolidated financial statements.

A. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

B. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

BASIS OF PRESENTATION

BASIS OF PRESENTATION

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.

USE OF ESTIMATES

USE OF ESTIMATES

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

REVENUE RECOGNITION

REVENUE RECOGNITION

Revenue is recognized by the Company when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently the company does not have products to sell.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE

Receivables are generally collected within 14 days of billing to the State of Louisiana. Rejected claims are and maybe resubmitted up to a year following the initial billing claim. The Company reviews its outstanding claims

on an annual basis and adjusts them appropriately. Currently the company maintains a reserve of $3,000 for rejected claims.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

Furniture and fixtures	5 to 10 years
Computer equipment	5 years
Equipment	5 to 10 years
Software	3 to 5 years

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

LONG-LIVED ASSETS

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.

ADVERTISING COSTS

ADVERTISING COSTS

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were $1,189 for the year ended December 31, 2012. Such costs are expensed when incurred.

INCOME TAXES

INCOME TAXES

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.

FAIR VALUE OF FINANCIAL INSTRUMENTS

FAIR VALUE OF FINANCIAL INSTRUMENTS

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.

RECLASSIFICATIONS

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current year presentation.

RECENT ACCOUNTING PRONOUNCEMENTS

RECENT ACCOUNTING PRONOUNCEMENTS

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

XML

Pro Forma Financial Information (Tables)

12 Months Ended

Dec. 31, 2012

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Proforma Information

		For the year ended August 31, 2012
			Pro Forma
		Historical	Adjustments		Pro Forma
Revenues		$                         -	$          2,860,429	(A)	$             195,067
Cost of revenues		-	2,362,245	(A)	-
	Gross profit	-	498,184		195,067
	General and administrative	130,769	517,813	(A)	195,067
	Depreciation and amortization	450	1,245	(A)	1,471
	Total operating expenses	131,219	519,058		196,538
	Loss from operations	(131,219)	(20,874)		(1,471)
Other income (expense):
	Interest and finance charges	(10,768)	(1,437)	(A)	(14,707)
	Interest and finance charges - related parties	(25,312)	-		(18,241)
	Loss on conversion of notes payable - related parties	(92,758)	-		-
	Induced conversion expense	(25,402)	-		(6,076)
	Loss on disposal of assets	(110)	-		-
	Other expenses	-	10,146	(A)	(47)
	Total other income (expense)	(154,350)	8,709		(39,071)
Loss from operations		(285,569)	(12,165)		(40,542)
	Less loss attributable to noncontrolling interest	(14)	-		(13)
Net loss before income taxes		(285,555)	(12,165)		(40,529)
Income taxes		-	-		-
Net loss attributable to common shareholders		$           (285,555)	$             (12,165)		$             (40,529)
Loss per common share, basic and diluted:		$                 (0.01)			$                 (0.00)
Weighted average number of shares
	outstanding - basic and diluted	54,443,649			47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	27,484	(B)	$	29,415
Accounts receivable (net of $3,000 allowance)		—			423,915	(B)		423,915
Prepaid expenses and other current assets		2,993			4,090	(B)		7,083
Total current assets		4,924			455,489			460,413
Property and equipment (net of accumulated depreciation)		1,481			46,845	(B)		48,326
Total assets	$	6,405		$	502,334		$	508,739
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	—		$	—
Accounts payable and other accrued expenses		142,990			18,542	(B)		161,532
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			18,542			252,323
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			18,542			612,348
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized
129,062 and 129,062 shares issued and outstanding at
August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(B)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		468,424	(B)		134,442
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		483,792			(103,609	)
Total liabilities and stockholders' deficit	$	6,405		$	502,334		$	508,739

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2012

	For the year ended August 31, 2012
				Pro Forma
	Historical			Adjustments			Pro Forma
ASSETS
Current Assets:
Cash and cash equivalents	$	1,931		$	53,805	(A)	$	55,736
Accounts receivable (net of allowance)		—			222,664	(A)		222,664
Prepaid expenses and other current assets		2,993			—			2,993
Total current assets		4,924			276,469			281,393
Property and equipment (net of accumulated depreciation)		1,481			30,701	(A)		32,182
Total assets	$	6,405		$	307,170		$	313,575
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Line of credit payable	$	—		$	41,612	(A)	$	41,612
Accounts payable and other accrued expenses		142,990			11,163	(A)		154,153
Accrued interest payable		42,575			—			42,575
Accrued interest payable - related parties		48,216			—			48,216
Total current liabilities		233,781			52,775			286,556
Long-term liabilities:
Convertible notes payable - (net of discount of $0 and $0)		125,000			—			125,000
Convertible notes payable - related parties (net of discount of $0 and $0)		235,025			—			235,025
Total long-term liabilities		360,025			—			360,025
Total liabilities		593,806			52,775			646,581
Stockholders' Deficit:
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively		129			—			129
Common stock, par value $.001 per share; 200,000,000 shares authorized;								—
57,563,258 and 50,998,814 shares issued and outstanding at								—
August 31, 2012 and August 31, 2011, respectively		57,563			—			57,563
Additional paid-in capital		57,697,233			15,368	(A)		57,712,601
Accumulated deficit prior to reentering development stage		(58,004,869	)		—			(58,004,869	)
Deficit accumulated during the development stage		(333,982	)		239,027	(A)		(94,955	)
Noncontrolling interest		(3,475	)		—			(3,475	)
Total stockholders' deficit		(587,401	)		254,395			(333,006	)
Total liabilities and stockholders' deficit	$	6,405		$	307,170		$	313,575

See accompanying notes to unaudited pro forma condensed consolidated financial information.

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED AUGUST 31, 2011

	For the year ended August 31, 2011
				Pro Forma
	Historical			Adjustments			Pro Forma
Revenues	$	—		$	2,875,579	(B)	$	195,067
Cost of revenues		—			2,339,789	(B)		—
Gross profit		—			535,790			195,067
General and administrative		130,769			548,380	(B)		195,067
Depreciation and amortization		450			—			1,471
Total operating expenses		131,219			548,380			196,538
Loss from operations		(131,219	)		(12,590	)		(1,471	)
Other income (expense):
Interest and finance charges		(10,768	)		(124	)(B)		(14,707	)
Interest and finance charges - related parties		(25,312	)		—			(18,241	)
Loss on conversion of notes payable - related parties		(92,758	)		—			—
Induced conversion expense		(25,402	)		—			(6,076	)
Loss on disposal of assets		(110	)		—			—
Other expenses		—			1,945	(B)		(47	)
Total other income (expense)		(154,350	)		1,821			(39,071	)
Loss from operations		(285,569	)		(10,769	)		(40,542	)
Less loss attributable to noncontrolling interest		(14	)		—			(13	)
Net loss before income taxes		(285,555	)		(10,769	)		(40,529	)
Income taxes		—			—			—
Net loss attributable to common shareholders	$	(285,555	)	$	(10,769	)	$	(40,529	)
Loss per common share, basic and diluted:	$	(0.01	)				$	(0.00	)
Weighted average number of shares
outstanding - basic and diluted		54,443,649						47,915,734

See accompanying notes to unaudited pro forma condensed consolidated financial information.

The following is a description of the pro forma adjustments to the historical condensed consolidated financial statements.

A. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

B. The increase of assets, liabilities, equity, revenues and expenses represents the acquisition of Angels of Mercy, Inc as if the sale occurred on August 31, 2012.

XML

SUBSEQUENT EVENTS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Abstract]
Purchase consideration	$ 100,000
Promissory note issued for purchase	550,000
Warrants issued	1,000,000
Warrant price per share	$ 0.015
Broker fees	$ 65,000

XML

Shareholders Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Earnings (Deficit)	Total
Beginning Balance, Value at Dec. 31, 2011	$ 1,000	$ 14,368	$ 190,762	$ 206,130
Beginning Balance, Shares at Dec. 31, 2011	1,000
Net loss			(40,723)	(40,723)
Ending Balance, Value at Dec. 31, 2012	$ 1,000	$ 14,368	$ 150,039	$ 165,407
Ending Balance, Shares at Dec. 31, 2012	1,000

XML

STATEMENT OF CASH FLOWS

12 Months Ended

Dec. 31, 2012

Supplemental Cash Flow Elements [Abstract]

STATEMENT OF CASH FLOWS

NOTE 4 – STATEMENT OF CASH FLOWS

For the year ended December 31, 2012, there are no supplemental non-cash investing and financing activities disclosures.

XML

SUBSEQUENT EVENTS - Purchase Price (Details) (USD $)	Dec. 31, 2012
Subsequent Events [Abstract]
Cash and cash equivalents	$ 27,121
Accounts receivable (net)	111,581
Prepaid expenses and other current assets	7,851
Property and equipment	57,000
Purchased goodwill	478,721
Total assets acquired	682,274
Accounts payable and other accrued expenses	9,688
Total liabilities assumed	$ 9,688